[1] J.W. Newburger, M. Takahashi, M.A. Gerber, M.H. Gewitz, L.Y. Tani, J.C. Burns, et al., Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, Pediatrics 114(6) (2004) 1708.
[2] R. Uehara, E.D. Belay, R.A. Maddox, R.C. Holman, Y. Nakamura, M. Yashiro, et al., Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan, Pediatric Infectious Disease Journal 27(2) (2008) 155.
[3] J.W. Newburger, L.A. Sleeper, B.W. Mccrindle, L.L. Minich, W.M. Gersony, V.L. Vetter, et al., Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki Disease, The New England journal of medicine 356(7) (2007) 663-675.
[4] Y. Kijima, T. Kamiya, A. Suzuki, O. Hirose, H. Manabe, A Trial Procedure to Prevent Aneurysm Formation of the Coronary Arteries by Steroid Pulse Therapy in Kawasaki Disease : THE 6th CONFERENCE ON PREVENTION FOR RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE, Japanese Circulation Journal-english Edition 46(11) (1982) 1239-1242.
[5] A.H. Tremoulet, S. Jain, P. Jaggi, S. Jimenezfernandez, J. Pancheri, X. Sun, et al., Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial, The Lancet 383(9930) (2014) 1731-1738.
[6] M.B. Son, K. Gauvreau, J.C. Burns, E. Corinaldesi, A.H. Tremoulet, V.E. Watson, et al., Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective Study, The Journal of pediatrics 158(4) (2011) 644-649.
[7] K. Sonoda, M. Mori, T. Hokosaki, S. Yokota, Infliximab Plus Plasma Exchange Rescue Therapy in Kawasaki Disease, The Journal of pediatrics 164(5) (2014) 1128-1132.
[8] T. Hokosaki, M. Mori, T. Nishizawa, T. Nakamura, T. Imagawa, M. Iwamoto, S. Yokota, Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease, Pediatrics International 54(1) (2012) 99-103.
[9] A.H. Tremoulet, P. Pancoast, A. Franco, M. Bujold, C. Shimizu, Y. Onouchi, et al., Calcineurin Inhibitor Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease, The Journal of pediatrics 161(3) (2012) 506-512.
[10] H. Suzuki, M. Terai, H. Hamada, T. Honda, T. Suenaga, T. Takeuchi, et al., Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin, Pediatric Infectious Disease Journal 30(10) (2011) 871-876.
[11] G. Ohshio, F. Furukawa, H. Fujiwara, Y. Hamashima, Hepatomegaly and splenomegaly in Kawasaki disease, Pediatric pathology / affiliated with the International Paediatric Pathology Association 4(3-4) (1985) 257-64.
[12] M. Eladawy, S.R. Dominguez, M.S. Anderson, M.P. Glode, Abnormal liver panel in acute kawasaki disease, The Pediatric infectious disease journal 30(2) (2011) 141-4.
[13] T. Sano, S. Kurotobi, K. Matsuzaki, T. Yamamoto, I. Maki, K. Miki, et al., Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment, European journal of pediatrics 166(2) (2007) 131-137.
[14] Y. Tang, W. Yan, L. Sun, J. Huang, W. Qian, Y. Ding, H. Lv, Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population, Clinical rheumatology 35(11) (2016) 2771-2776.
[15] M. Lin, C. Chang, L. Sun, H. Liu, H. Chang, C. Chen, et al., Risk factors and derived formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease, Journal of The Formosan Medical Association 115(5) (2016) 350-355.
[16] S. Yang, R. Song, J. Zhang, X. Li, C. Li, Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing, Archives of disease in childhood 104(3) (2019) 262-267.
[17] X. Liu, K. Zhou, Y. Hua, M. Wu, L. Liu, S. Shao, C. Wang, Prospective Evaluation of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio for Intravenous Immunoglobulin Resistance in a Large Cohort of Kawasaki Disease Patients, The Pediatric infectious disease journal 39(3) (2020) 229-231.
[18] S. Shao, C. Luo, K. Zhou, Y. Hua, M. Wu, L. Liu, et al., Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study, Pediatric rheumatology online journal 17(1) (2019) 78.
[19] S. Davies, N. Sutton, S. Blackstock, S. Gormley, C.J. Hoggart, M. Levin, J.A. Herberg, Predicting IVIG resistance in UK Kawasaki disease, Archives of disease in childhood 100(4) (2015) 366-8.
[20] D. Rigante, L. Andreozzi, M. Fastiggi, B. Bracci, M.F. Natale, S. Esposito, Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome, International journal of molecular sciences 17(3) (2016) 278.
[21] L.A. Sleeper, L.L. Minich, B.M. McCrindle, J.S. Li, W. Mason, S.D. Colan, et al., Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance, The Journal of pediatrics 158(5) (2011) 831-835.e3.
[22] S. Shimose, H. Iwamoto, T. Niizeki, T. Shirono, Y. Noda, N. Kamachi, et al., Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treat ed with Lenvatinib: A Multicenter Retrospective Study, Cancers (Basel) 12(7) (2020).
[23] R. Miksad, I. Cicin, Y. Chen, H. Klumpen, S. Kim, Z. Lin, et al., Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versu s placebo in patients with advanced hepatocellular carcinoma (HCC), Annals of oncology : official journal of the European Society for Medical Oncology 30 Suppl 4 (2019) iv134.
[24] A.W.H. Chan, J. Zhong, S. Berhane, H. Toyoda, A. Cucchetti, K. Shi, et al., Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection, Journal of hepatology 69(6) (2018) 1284-1293.
[25] Y.Y. Wang, J.H. Zhong, Z.Y. Su, J.F. Huang, S.D. Lu, B.D. Xiang, et al., Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatoc ellular carcinoma, Br J Surg 103(6) (2016) 725-734.
[26] P.J. Johnson, S. Berhane, C. Kagebayashi, S. Satomura, M. Teng, H.L. Reeves, et al., Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach -the ALBI grade, J Clin Oncol 33(6) (2015) 550-8.
[27] K. Yamamoto, T. Honda, T. Ito, Y. Ishizu, T. Kuzuya, M. Nakamura, et al., The relationship between oral-origin bacteria in the fecal microbiome and albumin-bilirubin grade in patients with hepatitis C, Journal of gastroenterology and hepatology 36(3) (2021) 790-799.
[28] L. Shi, D. Zhang, J. Zhang, Albumin-bilirubin score is associated with in-hospital mortality in critically ill patients with acute pancreatitis, Eur J Gastroenterol Hepatol 32(8) (2020) 963-970.
[29] T. Nakajima, Y. Karino, S. Hige, H. Suii, R. Tatsumi, M. Yamaguchi, et al., Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients, Journal of gastroenterology and hepatology 36(2) (2021) 367-375.
[30] S. Bayers, S.T. Shulman, A.S. Paller, Kawasaki disease : Part II. Complications and treatment, Journal of the American Academy of Dermatology 69(4) (2013) 513.e1-513.e8.
[31] G.B. Haycock, G.J. Schwartz, D.H. Wisotsky, Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults†, The Journal of pediatrics 93(1) (1978) 62-66.
[32] T. Saji, Y. Arakaki, S. Fuse, K. Hamaoka, H. Kato, T. Kobayashi, et al., A New Z -Score Curve of the Coronary Arterial Internal Diameter Using the Lambda-Mu-Sigma Method inaPediatric Population, Journal of the American Society of Echocardiography 29(8) (2016) 794-801.e29.
[33] M. Rimini, G. Rovesti, A. Casadei-Gardini, Child Pugh and ALBI grade: past, present or future?, Ann Transl Med 8(17) (2020) 1044.
[34] D. Feng, M. Wang, J. Hu, S. Li, S. Zhao, H. Li, L. Liu, Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases, Ann Transl Med 8(8) (2020) 553.
[35] M. Deng, S.W.Y. Ng, S.T. Cheung, C.C.N. Chong, Clinical application of Albumin-Bilirubin (ALBI) score: The current status, Surgeon 18(3) (2020) 178-186.
[36] T.I. Huo, ALBI grade as a new player in hepatocellular carcinoma, Journal of the Chinese Medical Association : JCMA 82(1) (2019) 1.
[37] M. Ringelhan, D. Pfister, T. O'Connor, E. Pikarsky, M. Heikenwalder, The immunology of hepatocellular carcinoma, Nat Immunol 19(3) (2018) 222-232.
[38] J.M. Llovet, J. Zucman-Rossi, E. Pikarsky, B. Sangro, M. Schwartz, M. Sherman, G. Gores, Hepatocellular carcinoma, Nat Rev Dis Primers 2 (2016) 16018.
[39] C.N. Jenne, P. Kubes, Immune surveillance by the liver, Nat Immunol 14(10) (2013) 996-1006.
[40] T. Kobayashi, Y. Inoue, K. Takeuchi, Y. Okada, K. Tamura, T. Tomomasa, et al., Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki Disease, Circulation 113(22) (2006) 2606.
[41] K. Egami, H. Muta, M. Ishii, K. Suda, Y. Sugahara, M. Iemura, T. Matsuishi, Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease, The Journal of pediatrics 149(2) (2006) 237-240.
[42] P.-p. Fu, Z.-d. Du, Y.-s. Pan, Novel Predictors of Intravenous Immunoglobulin Resistance in Chinese Children with Kawasaki Disease, The Pediatric infectious disease journal 32(8) (2013) e319-e323.
[43] K.P. Moon, B.J. Kim, K.J. Lee, J.H. Oh, J.W. Han, K.Y. Lee, S.J. Lee, Prediction of nonresponsiveness to medium-dose intravenous immunoglobulin (1 g/kg) treatment: an effe ctive and safe schedule of acute treatment for Kawasaki disease, Korean journal of pediatrics 59(4) (2016) 178-82.